QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery
Diseases of the Cardiovascular System | Diseases of the Kidney & Urinary Tract
What is the purpose of this trial?
This trial is designed to evaluate QPI-1002 versus placebo for the prevention of Major Adverse Kidney Events (MAKE) in subjects at high risk for acute kidney injury following cardiac surgery. Half of the participants will receive QPI-1002 while the other half will receive placebo.
- Ages18 years and older
- Trial withQuark Pharmaceuticals
- Start Date03/03/2019
- End Date07/30/2021
- Last Updated07/15/2019
- Study HIC#2000024823